Dustin Vidrine stands outside his house in Lafayette, La.
Annie Flanagan for NPR
hide caption
toggle caption
Annie Flanagan for NPR
Dustin Vidrine is facing the challenges of retinitis pigmentosa, a rare inherited eye disease that is causing his vision to deteriorate gradually.
As he entered his 20s, Vidrine noticed a narrowing of his field of vision, particularly when looking at screens like computers and TVs.
Parenting presented new obstacles for Vidrine, such as struggling to measure baby formula due to his vision limitations.
Desperate for a solution, Vidrine explored gene therapy as a potential treatment to preserve his vision, but accessing this advanced care proved to be a complex process.
Gene therapies, though revolutionary, come with a hefty price tag, making them inaccessible to many patients.
Vidrine’s hopes were dashed when he discovered that the gene therapy available on the market was not suitable for his specific genetic mutation.
Despite facing roadblocks, Vidrine remains determined to find a solution and preserve his vision.
Vidrine’s journey highlights the disparities in access to gene therapy treatments, with certain states having more facilities offering these therapies than others.
Efforts are being made to address these access disparities, including initiatives by organizations like Aradigm and the Center for Medicare & Medicaid Innovation.
As Vidrine continues to navigate the complexities of accessing gene therapy, he remains hopeful for a positive outcome.
